Cruz CR, Bollard CM. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica. 2015;100:709–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dierckx de Casterlé I, Billiau AD, Sprangers B. Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango. Blood Rev. 2018;32:449–56.

Article  PubMed  Google Scholar 

Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, French ITAC group and the EBMT Solid Tumour Working Party, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006;17(1134):1140.

Google Scholar 

Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886–92.

Article  PubMed  Google Scholar 

Takahashi T, Omuro Y, Matsumoto G, Sakamaki H, Maeda Y, et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas. 2004;28:e65–9.

Article  PubMed  Google Scholar 

Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, European Group for Blood and Marrow Transplantation Solid Tumors Working Party, et al. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European group for blood and marrow transplantation. Haematologica. 2007;92(418):420.

Google Scholar 

Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer. 2002;101:52–60.

Article  CAS  PubMed  Google Scholar 

Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318–20.

Article  PubMed  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(1703):1719.

Google Scholar 

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

Article  PubMed  PubMed Central  Google Scholar 

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kewan T, Bahaj W, Durmaz A, Aly M, Ogbue OD, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768–72.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.

Article  PubMed  Google Scholar 

Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open. 2021;6: 100114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153.

Article  PubMed  PubMed Central  Google Scholar 

Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, et al. VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors—efficacy, safety, and biomarker results. Clin Cancer Res. 2022;28:3256–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425–37.

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.

Article  CAS  PubMed  Google Scholar 

Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221–34.

Article  CAS  PubMed  Google Scholar 

Barisic S, Childs RW. Graft-versus-solid-tumor effect: from hematopoietic stem cell transplantation to adoptive cell therapies. Stem Cells. 2022;40:556–63.

Article  PubMed  PubMed Central  Google Scholar 

Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–5.

Article  CAS  PubMed  Google Scholar 

Santos N, Rodríguez-Romanos R, Nieto JB, Buño I, Vallejo C, et al. GvHD/immunotherapy working party of the spanish group of hematopoietic transplant (GETH). UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. Bone Marrow Transplant. 2016;51(79):82.

Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

Article  CAS  PubMed  Google Scholar 

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, et al. The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–24.

Article  PubMed  Google Scholar